60
Participants
Start Date
February 28, 2007
Primary Completion Date
January 31, 2014
Study Completion Date
July 31, 2014
capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin)
"Capecitabine will be administered orally at a twice daily dose of 850 mg/m2 (equivalent to a total daily dose of 1700 mg/m2) given days 1-14 of the three week cycle.~Oxaliplatin will be administered at the dose of 130 mg/m2 given as a 2-hour intravenous infusion on day 1 of a three week cycle.~Bevacizumab will be administered at a dose of 15 mg/kg given as a 30-90 minute intravenous infusion on day 1 of a three week cycle following the administration of oxaliplatin."
Duke University Medical Center, Durham
University of Wake Forest Baptist Medical Center, Winston-Salem
Lead Sponsor
Collaborators (2)
Hoffmann-La Roche
INDUSTRY
Sanofi
INDUSTRY
Genentech, Inc.
INDUSTRY
Duke University
OTHER